Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash Flows From Operating Activities:
Net loss	$ (120,011)	$ (91,248)	$ (69,770)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	28,409	27,972	26,492
Stock-based compensation	17,483	15,139	13,670
Accretion of debt discount on 2018 Convertible Notes, recorded to interest expense (Note 15)	1,931	4,890	5,710
Amortization of deferred financing costs on 2018 Convertible Notes, recorded to interest expense (Note 15)	220	567	696
Bad debt expense (recovery)	12	(17)	57
Unrealized loss (gains) from transactions denominated in foreign currency	10	(23)	(153)
Loss on 2018 Convertible Note purchase (Note 15)	0	845	25
Change in cash surrender value of corporate-owned life insurance policy	(5)	(418)	(137)
Deferred tax liabilities	31	(5,237)	(104)
Income tax recognition on unrealized gain for available-for-sale securities	0	(9,651)	(2,217)
Unrealized gains on marketable securities (Note 3(a))	(10,458)	0	0
Change in fair value of contingent consideration related to the Talon and EVOMELA acquisitions (Note 10)	(1,927)	4,957	649
Research and development expense recognized for the value of common stock issued in connection with QAPZOLA (Note 17(b)(x)) and ROLONTIS (Note 17(b)(xiii)) milestone achievements	0	0	2,419
Changes in operating assets and liabilities:
Accounts receivable, net	2,844	7,694	(9,494)
Other receivables	(1,571)	3,663	6,895
Inventories	3,390	4,318	(5,800)
Prepaid expenses	(3,642)	(6,137)	(423)
Other assets	5,010	1,573	(2,043)
Accounts payable and other accrued obligations	11,382	5,518	(4,033)
Accrued payroll and benefits	592	280	790
FOLOTYN development liability	(389)	(744)	(1,556)
Acquisition-related contingent obligations	0	0	(1,300)
Contract liabilities	4,850
Deferred revenue	0	593	(2,985)
Other long-term liabilities	(564)	(3,389)	2,153
Net cash used in operating activities	(62,403)	(38,855)	(40,459)
Cash Flows From Investing Activities:
Proceeds from redemption of corporate-owned life insurance policy	4,130	0	0
Payment for corporate-owned life insurance premiums	0	(601)	(601)
Purchases of property and equipment	(107)	(465)	(78)
Cash paid for KHAPZORY distribution rights (Note 3(g))	(2,650)	0	0
Purchase of equity securities (Note 11)	0	(15)	0
Net cash provided by (used in) investing activities	1,373	(1,081)	(679)
Cash Flows From Financing Activities:
Proceeds from employees for exercises of stock options, net	13,475	5,477	203
Proceeds from sale of stock under our employee stock purchase plan	1,122	1,010	668
Proceeds from employees, for our remittance to tax authorities, upon vesting of restricted stock	4,645	0	0
Payments to tax authorities upon employees' surrender of restricted stock at vesting and exercises of stock options	(27,679)	(4,331)	(1,397)
Payment of principal upon the maturity of the 2018 Convertible Notes (Note 15)	(20)	0	0
Payment of contingent consideration related to EVOMELA acquisition (Note 10(b))	0	0	(4,700)
Purchase of 2018 Convertible Notes (Note 15)	0	(27,500)	(9,014)
Purchase of warrants related to the conversion hedge of 2018 Convertible Notes (Note 15)	0	(27,189)	(330)
Proceeds from sale of call options related to the conversion hedge of 2018 Convertible Notes (Note 15)	0	32,982	351
Proceeds from sale of common stock under an at-the-market sales agreement (Note 7)	0	128,272	73,869
Dividends paid upon conversion of Series E Convertible Voting Preferred Stock (Note 7)	0	0	(6)
Net cash (used in) provided by financing activities	(8,457)	108,721	59,644
Effect of exchange rates on cash and equivalents	(356)	316	(25)
Net (decrease) increase in cash and cash equivalents	(69,843)	69,101	18,481
Cash and cash equivalents — beginning of year	227,323	158,222	139,741
Cash and cash equivalents — end of year	157,480	227,323	158,222
Supplemental Disclosure of Cash Flow Information:
Cash paid for income taxes	45	17	11
Cash paid for interest	$ 1,031	$ 2,692	$ 3,300